Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia

• Published in: International journal of ophthalmology Vol. 10; no. 12; pp. 1889 - 1897
• Main Authors: Mohamad, Nur Afiqah, Ramachandran, Vasudevan, Ismail, Patimah, Mohd Isa, Hazlita, Chan, Yoke Mun, Ngah, Nor Fariza, Md Bakri, Norshakimah, Ching, Siew Mooi, Hoo, Fan Kee, Wan Sulaiman, Wan Aliaa
• Format: Journal Article
• Language: English
• Published: China International Journal of Ophthalmology Press 18.12.2017; Press of International Journal of Ophthalmology (IJO PRESS)
• Subjects: 1897; anti-vascular endothelial growth factor therapy; Investigation; photodynamic therapy; ranibizumab; treatment patterns; anti-vascular endothelial growth factor therapy; photodynamic therapy; ranibizumab; treatment patterns
• ISSN: 2222-3959; 2227-4898
• DOI: 10.18240/ijo.2017.12.16

To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. Study subjects were recruited retrospectively using the Electronic Medical Record (EMR) database software in Hospital Selayang. Demographic data, medical history, diagnostic procedure, treatments and diagnosis of patients were recorded. The five-year analysis included 821 patients with a mean age of 65.9±11.73y. Overall, there were a higher number of males (63.1%) and a higher number of Chinese (47.4%) patients. Among the 821 patients, 62.9% received ranibizumab injection followed by 19.2% PDT therapy and 17.9% had ranibizumab combined with PDT therapy. Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) were the most common retinal eye diseases reported, recording prevalence of 25.0% and 45.6%, respectively. The trend in ranibizumab treatment was reported to increase while PDT showed a decrease in trend from year 2010 to 2014. In terms of treatment, following multiple logistic regression, AMD was associated with the subjects being more likely to have received ranibizumab monotherapy ( <0.001) while PCV was associated with more likely to have received PDT ( <0.001) and PDT combined with ranibizumab therapy ( <0.001). The tertiary care setting in Malaysia is consistent with management of patients from other countries whereby ranibizumab is the most common treatment given to patients with AMD, while PCV patients most commonly receive PDT and ranibizumab combined with PDT therapy.